Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical solution containing clomiphene citrate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing clomiphene are listed in tablet form. No clomiphene product of any kind is listed in solution form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Clomiphene is a selective estrogen receptor modulator, an ovulation-stimulating medicine, that compounding pharmacies prepare as oral capsules, tablets and liquids by prescription.
Clomiphene citrate is a non-steroidal medicine that binds estrogen receptors in the hypothalamus, pituitary and ovary. By competing with estrogen at those receptors it tricks the brain into releasing more of the gonadotropins that drive follicle growth and trigger ovulation. The manufactured product is Clomid (clomiphene citrate) tablets, distributed by Cosette Pharmaceuticals, plus generic tablets. Clomid is FDA-approved for treatment of ovulatory dysfunction in women who want to become pregnant, after other barriers to pregnancy have been excluded or treated; the label states that its benefit in male infertility has not been shown in adequate studies, and that testicular tumors and breast enlargement have been reported in men taking it. Prescribers may order clomiphene compounded when they want a strength below the single manufactured tablet, a capsule without specific fillers or a liquid form. Compounded preparations are not FDA-approved and require a prescription.
The Clomid label carries no boxed warning. Do not take clomiphene if you are pregnant, have liver disease, abnormal uterine bleeding of unknown cause, ovarian cysts or enlargement not due to polycystic ovary syndrome, uncontrolled thyroid or adrenal disease, or a pituitary tumor or other intracranial lesion. Stop the medicine and get a prompt eye examination for blurring, spots, flashes or other visual symptoms, which can be prolonged or irreversible. Ovarian hyperstimulation syndrome can develop quickly; report abdominal or pelvic pain, bloating, weight gain or shortness of breath right away. Clomiphene raises the chance of twins or more, and uterine fibroids may enlarge. Prolonged use may increase the risk of ovarian tumors. The label documents no drug interactions. Common side effects include flushing, upset stomach, breast discomfort and headache. Clomiphene is contraindicated in pregnancy, and the label advises caution in nursing women because it may reduce milk supply; lactation references report it was once used to suppress lactation. If you become pregnant, call your prescriber; for side effects that are severe or persistent, talk to your prescriber or pharmacist.
Clomiphene is a mixture of zuclomiphene (cis) and enclomiphene (trans) isomers with mixed estrogenic and antiestrogenic activity. It occupies hypothalamic and pituitary estrogen receptors, raising GnRH, LH and FSH; in women this produces follicular growth, an estradiol rise and a preovulatory gonadotropin surge, and in men it raises LH, FSH and testosterone. It is readily absorbed orally and excreted mainly in feces; zuclomiphene has the longer half-life, with detectable levels persisting for over a month and possible enterohepatic recycling, so active drug may persist into early pregnancy. Labeled indication: Clomid for ovulatory dysfunction in women desiring pregnancy, not beyond about six cycles. Prescribers have ordered compounded clomiphene for men with hypogonadism or infertility who wish to preserve spermatogenesis; a 2022 systematic review and meta-analysis in Andrology (Huijben et al., 19 studies) reported increases in total and free testosterone, LH and FSH with adverse events in under 10 percent of patients, and a 2016 review in Translational Andrology and Urology describes the use as off-label. Dosing and cycle length are per prescriber. Label monitoring: pelvic exam before each course, ovarian size between courses, triglycerides in hyperlipidemia, and ophthalmologic evaluation for visual symptoms. Clomiphene is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin using the applicator provided or a cotton swab. Let it dry before covering. Use an accurate measuring device if your label gives a volume. Keep it away from the eyes and avoid open flame if the solution contains alcohol. Wash your hands afterward.
Topical solutions are aqueous or alcohol based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Keep the bottle tightly closed at room temperature, away from heat and flame, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)
